Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Dose Reduction Strategies in Pregnancy
NCT03831113Phase 2Terminated
- Start
- Apr 2019
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) (2 arms). Primary endpoint: Visual Analog Scale Scores at 36 weeks. Started Apr 2019; status: terminated.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03831113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831113.